Navigation Links
Corena Therapeutics Launched Coresatin, a Nonsteroidal Cream Used to Treat Critical Skin Conditions and Infections
Date:5/10/2013

(PRWEB) May 10, 2013

Swiss based company, Corena Therapeutics has launched Coresatin in Pharmagora fair Paris at 6-8th April that was attended by leading dermatologists, doctors, physicians and leaders of industry from all over the world. Pharmagora 2013 hosted international dignitaries of pharmacists, doctors, industry leaders and saw the participation of more than 400 exhibitors and over 26.000 professionals from all over the world. The event has focused on the changing trends in pharmaceutical industry and latest products coming into the market. Corena Therapeutics used this fair as the launching pad to unveil its Coresatin brand consisting of highly customized products that optimize the therapeutic performance without the undesired side effects.

Upon WHO reports, skin disease is not a leading cause of mortality, it is not usually thought of as a major health issue in developing countries. However, it is extremely common; up to 21-87% of the population may be affected by some type of skin problem, depending on the locale. It also contributes to significant physical and psychological disabilities. These disabilities have been measured by a number of life quality measures, but the importance of skin health is often underestimated because of the chronic, non-life threatening nature of most skin diseases. Disfigurement and discomfort associated with skin problems make them among the main reasons people seek medical care, and are the cause of approximately 24% of primary care visits. Skin diseases in developing countries have a serious impact on people's quality of life, causing lost productivity at work and school, and discrimination due to disfigurement. Skin changes may also indicate the presence of more serious diseases that need treatment. In the past, such conditions were ignored or given low priority by health authorities because they did not, on the whole, kill people, and they often did not present in tertiary care centers. But now there is a big push at both national and international levels to train health workers in developing countries to improve diagnosis and treatment of dermatological conditions.

This product launch is aimed at securing a robust market presence where there are a lot of existing players. According to the executives, Coresatin products are used to treat several inflammatory skin disorders like psoriasis, dermatitis, eczema and other severe conditions like diabetic foot ulcers and fungal infections. Products are being marketed in US and Europe, to provide effective relief to those who are suffering from complex skin barrier dysfunctionality and other related conditions. Corena Therapeutics executives also claims that they are presenting innovative and safe alternatives to available treatments. The company focus on designing highly customized products that optimize the therapeutic performance without the undesired side effects and believe that these innovations will have great impact on improving human health.

About the Company

Corena Therapeutics is an emerging company dedicated to the development of novel products that will improve the quality of life in the field of dermatology. With a unique approach to skin disorders Corena Therapeutics’ mission is to present innovative and safe alternatives to available treatments. All the efforts focus on designing highly customized products that optimize the therapeutic performance without the undesired side effects. The strong scientific knowledge of distinguished team of scientists with a diverse scientific background and expertise come to life with innovative product developments and these innovations will have a great impact on improving human health.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10721452.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Global Peptide Therapeutics Market - New Market Research Report Published by Transparency Market Research
2. Liver Diseases Therapeutics Market - New Industry Research Report Published by Transparency Market Research
3. Ontario Genomics Institute invests in stem cell technology at Tissue Regenerative Therapeutics
4. Scientist receives $2.8 Million to study cell signaling mechanism and develop potential therapeutics
5. Cancer vaccine Special Focus series published in Human Vaccines & Immunotherapeutics
6. Research shows potential of microneedles to target therapeutics to the back of the eye
7. Media alert: 24th EORTC - NCI - AACR Symposium Molecular Targets and Cancer Therapeutics
8. FORMA Therapeutics teams with TGen Drug Development
9. The Ludwig Institute for Cancer Research announces launch of iTeos Therapeutics SA
10. Targeted therapeutics for colon cancer to be presented at AACR meeting
11. 5 Free Workout Routines for Men Launched from FreeWorkouts.info
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... ... Dr. Ronald E. Hawkins, vice president for academic affairs ... Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new dean of Liberty ... to Liberty from the Ohio University Heritage College of Osteopathic Medicine (OU-HCOM), where ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal 8: ... ’s true account of his paramedic experiences. Schanssema describes the tragedies he saw, as ... attempts to overcome them. , Schanssema, initially unsure of the career path he wanted ...
(Date:2/24/2017)... ... , ... Indiana Fiber Network (IFN) President and CEO Kelly C. Dyer recently ... as the Chairman of the Management Committee when IFN was originally formed in 2002 ... of investor/owners and development of the business plan. He became the first paid ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, the most ... Jensie Gran Fondo of Marin. For the second year in a row, cyclists ... sunscreen. , “We are thrilled to provide our safe, non-toxic sunscreen to over ...
(Date:2/23/2017)... ... February 23, 2017 , ... The American Cleft Palate-Craniofacial Association (ACPA) is pleased ... KLS is a longtime supporter of the event. , "We are pleased that KLS ... Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has a long track record of ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... Feb. 24, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the Cowen and Company 37 ... Marriott Copley Place on Tuesday, March 7, 2017 at ... webcast of the presentation can be accessed at ... following the conference via Zimmer Biomet,s Investor Relations website ...
(Date:2/24/2017)... , Feb. 24, 2017  In conjunction with ... 2016 financial results press release, you are invited to ... live over the internet on Tuesday, March 14, 2017 ... A live audio webcast of the presentation ... www.durect.com and clicking "Investor Relations."  If you are ...
(Date:2/24/2017)... 24. Februar 2017 ITL Limited, ( ... Gesundheitsbereiches, ist erfreut, für das zum 31. Dezember ... Vorjahreszeitraum exzellente Ergebnisse vorlegen zu können. Eine vollständige ... Wachstum" finden Sie hier . ... Steuern 2,12 Millionen USD (Dez. 2015: 1,04 Millionen USD; +104 %) ...
Breaking Medicine Technology: